Hypertension Management in Pre- and Post- Percutaneous Coronary Intervention - An Expert Opinion

Angiotensin receptor blockers (ARBs) are the most preferred antihypertensive agents among Indian cardiologists for managing hypertension in post-percutaneous coronary intervention (PCI) patients, an Indian expert opinion has revealed.

This first-of-its-kind expert opinion for managing hypertension in patients post PCI and with comorbidities has been published in the Journal of the Practice of Cardiovascular Sciences in April 2024.

336 non-interventional cardiologists and 256 interventional cardiologists participated in the expert opinion creation; which included a questionnaire on post-PCI management, followed by round table meetings.

Some key recommendations from the expert opinion include:

1) In monotherapy, ARBs were the most preferred antihypertensive agents for hypertension patients with different comorbidities*.

2) Metoprolol is the preferred choice among beta-blockers for post-PCI and heart failure patients.

3) Combination therapy with ARBs and beta-blockers is recommended for hypertensive patients with comorbidities.

*Arrhythmia, diabetes, dyslipidemia, HF, and stroke

ARBs: Angiotensin receptor blockers, PCI: Percutaneous Coronary Intervention

Adapted from:

Kumar AS, Kumar V, Shah CP, Kasturi S, Birla A, Revankar S, et al. Hypertension management in pre‑ and post percutaneous coronary intervention patients: An expert opinion of cardiologists from India. J Pract Cardiovasc Sci 2024;10:18-24.